We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Access Bio Inc

Access Bio is dedicated to the prevention and early diagnosis of infectious diseases through research, development, a... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Test for The Detection of G6PD Deficiency Evaluated

By LabMedica International staff writers
Posted on 07 Jan 2020
To reduce the risk of drug-induced hemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria.

The gold standard method for measuring G6PD activity is quantitative spectrophotometry, but this method is expensive and requires laboratory facilities that are often unavailable in malaria-endemic communities, especially in remote areas. More...
The fluorescent spot test (FST) is a qualitative alternative; however, it also requires laboratory infrastructure and extensive training for reliable interpretation.

An international team of scientists led by the Charles Darwin University (Darwin, Australia) carried out a systematic review and individual patient meta-analysis assessed the utility of a qualitative lateral flow assay from CareStart Screening test for G6PD deficiency (CSG, Access Bio/CareStart, Somerset, NJ, USA) for the diagnosis of G6PDd compared to the gold standard spectrophotometry using kits from Trinity Biotech PLC (Wicklow, Ireland).

All of the studies included were undertaken between 2014 and 2018. Six studies were conducted in Southeast Asia, one in Africa, and one in the Americas. In total, three studies (four countries, 2,845 participants) assessed G6PD status from capillary blood and three from venous blood (three countries, 2,066 participants). In one study, CSG and spectrophotometry were performed on both venous and capillary samples, and in one study CSG was performed on both venous and capillary samples; however, spectrophotometry was only performed on capillary blood.

A total of 5,815 individual participant data (IPD) were available, of which 5,777 results (99.3%) were considered for analysis, including data from 3,095 (53.6%) females. Overall, the CSG had a pooled sensitivity of 0.96 and a specificity of 0.95. When the prevalence of G6PDd was varied from 5% to 30%, the unconditional negative predictive value (NPV) was 0.99, with a positive likelihood ratio (LR+) and an LR− of 18.23 and 0.05, respectively. Performance was significantly better in males compared to females but did not differ significantly between samples collected from capillary or venous blood.

The authors concluded that the CSG performed well at the 30% threshold. Its high NPV suggests that the test is suitable to guide PQ treatment, and the high LR+ and low LR− render the test suitable to confirm and exclude G6PDd. In a comparison between Trinity spectrophotometry kits, considered for this analysis, and another spectrophotometry kit (Pointe Scientific, Canton, MI, USA), both assays showed a very good correlation. The study was published on December 13, 2019 in the journal Public Library of Science Medicine.

Related Links:
Charles Darwin University
Access Bio
Trinity Biotech PLC
Pointe Scientific



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Automated PCR Setup
ESTREAM
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.